RxDoctor Payments DataLook up a doctor →

John Anderson, MD

Internal Medicine · Nashville, TNNPI 1003801788

Payments from drug & device makers

$1,471,226in general payments, 2019–2025

Across 2,353 payments — averaging $625.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$574K
  • Sanofi-aventis U.S. LLC$236K
  • Novo Nordisk$226K
  • AstraZeneca$136K
  • Eli Lilly$76K
  • Corcept Therapeutics$43K
  • plus $180K from 42 others
$9,357in research payments, 2019–2025

Across 11 payments — averaging $850.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi-aventis U.S. LLC$9K

What the payments were for

  • Consulting fees$313,69521%
  • Speaking & faculty fees$1,046,30771%
  • Travel & lodging$77,4985%
  • Food & beverage$33,5712%
  • Education$660%
  • Gifts$590%
  • Other$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,471,226 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$100,322
Medicare patients
381
Services billed
1,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide153$170,664
JardianceEmpagliflozin137$151,331
TrulicityDulaglutide84$113,761
FarxigaDapagliflozin Propanediol91$100,708
OzempicSemaglutide73$89,575
EliquisApixaban63$72,385
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$68,323
XareltoRivaroxaban36$49,568
MyrbetriqMirabegron27$29,732
Soliqua 100-33Insulin Glargine/Lixisenatide14$24,687
LinzessLinaclotide26$19,781
JanuviaSitagliptin Phosphate27$18,996
EntrestoSacubitril/Valsartan16$18,318
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$14,333
Breo ElliptaFluticasone/Vilanterol12$10,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$574,143$288,434250 claims
Boehringer IngelheimJardiance$18,648$151,331137 claims
AstraZenecaFarxiga, Symbicort$135,949$107,313103 claims
Novo NordiskOzempic$226,310$89,57573 claims
GSKTrelegy Ellipta, Breo Ellipta$1,140$79,31384 claims
PfizerEliquis, Premarin$1,396$77,71783 claims
Johnson & JohnsonXarelto$37,653$49,56836 claims
Astellas Pharma US IncMyrbetriq$3,129$29,73227 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$236,156$24,68714 claims
AbbVieLinzess, Synthroid$715$22,92287 claims
MerckJanuvia$188$18,99627 claims
NovartisEntresto$4,373$18,31816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →